Name: Operating Profit Margin

Definition: Operating profit margin focuses on profits from the company’s core business — before interest payments and taxes. It reflects how well the business manages operating costs relative to sales. Strong operating margins show efficient day-to-day operations. Shrinking margins may reveal rising overhead, pricing weakness, or declining efficiency.

Interpretation:
• In '2021', MTNB's operating profit margin was -74954.5%, highlighting profit earned from core business operations. Industry average for Biotechnology: Pharmaceutical Preparations in '2021' stood at -185.4%.
• In '2022', MTNB's operating profit margin was -771.3%, highlighting profit earned from core business operations. The increase since '2021' reflects strengthening financial performance. Industry average for Biotechnology: Pharmaceutical Preparations in '2022' stood at -175.3%. Industry average increased by 10.1% compared to previous year.
• In '2023', MTNB's operating profit margin was -2168.4%, highlighting profit earned from core business operations. The decline from '2022' may indicate some operational or financial challenges. Industry average for Biotechnology: Pharmaceutical Preparations in '2023' stood at -144.9%. Industry average increased by 30.4% compared to previous year.
Overall, MTNB's operating profit margin has been volatile but showed an upward trend over the past 3 years.

Formula: Operating Profit Margin = Operating Income / Revenue

Good Range: Often 10%-30% depending on business model.